CUAMC
CRSP icon

China Universal Asset Management Company’s CRISPR Therapeutics CRSP Stock Holding History

China Universal Asset Management Company’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$837K Sell
15,350
-1,683
-10% -$88.7K 0.05% 221
2026
Q1 		$810K Sell
17,033
-3,496
-17% -$184K 0.06% 215
2025
Q4 		$1.08M Buy
20,529
+4,587
+29% +$275K 0.08% 182
2025
Q3 		$1.03M Sell
15,942
-1,404
-8% -$80.6K 0.09% 177
2025
Q2 		$844K Buy
17,346
+141
+0.8% +$5.46K 0.08% 187
2025
Q1 		$585K Sell
17,205
-893
-5% -$37.9K 0.05% 235
2024
Q4 		$712K Buy
18,098
+1,717
+10% +$81.1K 0.07% 208
2024
Q3 		$770K Buy
16,381
+6,405
+64% +$325K 0.08% 165
2024
Q2 		$539K Sell
9,976
-5,433
-35% -$314K 0.08% 140
2024
Q1 		$1.05M Buy
15,409
+6,216
+68% +$445K 0.13% 124
2023
Q4 		$575K Buy
9,193
+7,152
+350% +$395K 0.11% 136
2023
Q3 		$92.6K Buy
2,041
+1,007
+97% +$52K 0.03% 198
2023
Q2 		$58K Sell
1,034
-31
-3% -$1.76K 0.02% 181
2023
Q1 		$48.2K Sell
1,065
-2,533
-70% -$123K 0.02% 154
2022
Q4 		$146K Sell
3,598
-20,985
-85% -$1.11M 0.06% 109
2022
Q3 		$1.61M Buy
24,583
+23,250
+1,744% +$1.68M 0.68% 51
2022
Q2 		$81K Hold
1,333
– – 0.03% 77
2022
Q1 		$84K Buy
+1,333
New +$83.7K 0.03% 73

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

China Universal Asset Management Company's CRSP Position: Q2 2026 in Review

China Universal Asset Management Company reduced its CRISPR Therapeutics (CRSP) stake by 9.9% in Q2 2026, selling an estimated $88.7K and leaving 15,350 shares worth $837K. The position accounts for 0.05% of the portfolio, ranked #221.

China Universal Asset Management Company first reported a position in CRSP in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.61M in Q3 2022. 349 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • China Universal Asset Management Company held 15,350 shares of CRISPR Therapeutics worth $837K as of Q2 2026.
  • China Universal Asset Management Company sold 1,683 CRISPR Therapeutics shares in Q2 2026, an estimated $88.7K.
  • CRISPR Therapeutics made up 0.05% of China Universal Asset Management Company's portfolio in Q2 2026, its #221 holding.
  • China Universal Asset Management Company first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • China Universal Asset Management Company's CRISPR Therapeutics position peaked at $1.61M in Q3 2022.
  • 349 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.